AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway

AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway

Abstract Background Cisplatin is the first-line chemotherapy used against most upper aerodigestive tract carcinomas. In head and neck cancer, sensitivity to cisplatin remains the key issue in treatment response and outcome. Genetic heterogeneity and aberrant gene expression may be the intrinsic fact...

Full description

Bibliographic Details
Main Authors: Wei-Min Chang, Yu-Chan Chang, Yi-Chieh Yang, Sze-Kwan Lin, Peter Mu-Hsin Chang, Michael Hsiao
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
AKR1C1
Cisplatin-resistance
HNSCC
STATs
Ruxolitinib
Online Access:http://link.springer.com/article/10.1186/s13046-019-1256-2

Internet

http://link.springer.com/article/10.1186/s13046-019-1256-2

Similar Items